Eko Health

Eko Health develops digital stethoscopes and accompanying software intended to replace conventional acoustic stethoscopes in clinical practice. Its devices, including the CORE 500 stethoscope, combine digitally enhanced audio with active noise cancellation, real-time waveform display and 3-lead ECG capture, allowing clinicians to both hear and visually inspect heart sounds and ECG tracings during an exam. Exam recordings are stored automatically so results can be compared over time, shared for second opinions or reviewed with patients.

The device hardware is paired with FDA-cleared algorithms that screen for heart murmurs, atrial fibrillation and low ejection fraction, plus health-system integrations and a platform marketed as SENSORA. The company reports nine FDA clearances, more than 750,000 devices sold and clinical validation across more than 70 publications, and cites research indicating that providers using its technology are twice as likely to detect heart disease. Its telehealth-compatible configuration is positioned for use in both virtual and in-person settings, including high-acuity care at home.

Eko addresses three stated segments: individual providers who purchase devices directly, health systems deploying its algorithms across clinical teams, and life-science organizations using the technology for clinical trial recruitment, cardiac and pulmonary screening, and patient safety monitoring. A separate veterinary application, developed with Boehringer Ingelheim, applies murmur-detection AI to dogs.

Business model

Eko sells stethoscope hardware and bundles directly to individual clinicians through an online store, and licenses AI algorithms and platform integrations to health systems and life-science organizations at enterprise scale. The company notes that device purchases may qualify for reimbursement.

Revenue derives from sales of digital stethoscope devices and bundles to clinicians, alongside enterprise offerings of AI software and health-system integrations, and services for life-science and clinical trial customers.

Traction

The company reports more than 750,000 devices sold, nine FDA clearances and clinical validation in more than 70 publications. Named customer references include Sutter Health, Guthrie, Wayne General Hospital and Origin Healthcare. A real-world evaluation of its AI-enabled stethoscopes in primary care, the TRICORDER study, was published in The Lancet.

Latest developments

Recent announcements include the appointment of Dr. Steven Steinhubl as Chief Medical Officer, publication of the TRICORDER study in The Lancet, a joint launch with Boehringer Ingelheim of an AI solution that detects heart murmurs in dogs, a customer milestone of 750,000 devices sold, and deployments of Eko SENSORA at sites such as Wayne General Hospital.